Levetiracetam for Benign Rolandic Epilepsy

Johns Hopkins University

Status and phase: Completed; Phase 4

Conditions: Epilepsy

Treatments: Drug: Levetiracetam

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00181116

05-02-18-06

Details and patient eligibility

About

This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.

Full description

This is a 6 month study in which children on another anticonvulsant would have EEG, language testing, and a clinic visit at baseline. They would then be rapidly transitioned off of their current anticonvulsant and onto levetiracetam (Keppra). Repeat EEG and language testing would be done after 6 months to evaluate for improvement.

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ages 6-12
• Benign rolandic epilepsy
• Language difficulties as reported by parents or teachers
• On another anticonvulsant other than levetiracetam

Exclusion criteria

• Prior use of levetiracetam
• On 2 or more anticonvulsants
• Language problems prior to epilepsy
• Another seizure disorder
• Status epilepticus within the past 6 months
• Significant psychiatric disease
• Progressive neurologic disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)